Health Canada

NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine

Retrieved on: 
Thursday, April 4, 2024
Neurology, University, Vii, Disability, Sound, Pfizer, CGRP, Headache, Migraine, Ageing, Light, Health Canada, Nausea, Myenteric plexus

KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.

Key Points: 
  • KIRKLAND, QC, April 4, 2024 /CNW/ - NURTEC ODT® (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age.iii NURTEC is an orally disintegrating calcitonin gene-related peptide (CGRP) receptor antagonist tablet.
  • "It is an exciting time for Canadians to now have another targeted, migraine specific therapy in their management toolbox."
  • People living with migraine are looking for timely and equitable access to new options to effectively manage this highly debilitating disease," said Wendy Gerhart from Migraine Canada.
  • "Pfizer Canada is proud to bring this new therapy to Canadians impacted by migraine," said Andréa Mueller, Primary Care Portfolio Lead, Pfizer Canada.

/R E M I N D E R -- Travelling for Easter? The Canada Border Services Agency gives tips for a smooth trip/

Retrieved on: 
Thursday, March 28, 2024
Firearm, Narcotic, Friends, Canadian Food Inspection Agency, Letter, Oil, Poultry, Travel, BIS, CBSA, Child, Bird, Tobacco, Food, Health Canada, Cannabis, Holiday, Atmosphere, Water, Arrest, Safety, THC, Family, AIRS, Movement, Canada Border Services Agency, Cannabidiol, Drug

Here are some tips to help you plan for your trip:

Key Points: 
  • Here are some tips to help you plan for your trip:
    Plan ahead, expect delays and check border wait times .
  • Travellers crossing the border by land are encouraged to cross during non-peak hours such as early mornings.
  • Border services officers are always watching for missing children , and in the absence of the letter, officers may ask additional questions.
  • You may also contact Border Information Service (BIS) line toll-free within Canada at 1-800-461-9999 for more information

triLift By Lumenis Receives Medical Device License from Health Canada, Launches in Canada

Retrieved on: 
Monday, March 25, 2024
Facial muscles, Facial, DOI, Face, Eye, Patient, SAN, Gold, Aesthetics, RF, MDL, IPL, Health Canada, Eyelid, CO2, Intense, Skin, Invention, Vision, Laser, Region, Cosmetic, Physician, Muscle atrophy, Ageing, Medical imaging

SAN JOSE, Calif., March 25, 2024 /PRNewswire/ -- Lumenis Be, Ltd., a global leader in developing and commercializing energy-based solutions for the Aesthetic and Vision markets, is proud to announce that the Facial Muscle Stimulation treatment that has taken over the U.S. is now coming to Canada. triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.

Key Points: 
  • triLift, the groundbreaking Dynamic Muscle Stimulation technology (DMSt™), has received a Medical Device License (MDL) from Health Canada.
  • Finally, practitioners in Canada can go beyond the skin, to address a key cause of facial aging—the muscles.
  • triLift by Lumenis is a unique device, allowing providers to target a patient's specific need with a quick, comfortable treatment option.
  • "The clearance of triLift by Health Canada is a significant moment in the Canadian facial aesthetics market," said Lumenis Vice President & Regional President, Americas, Brad Oliver.

AUXLY REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES OUTLOOK FOR 2024

Retrieved on: 
Monday, March 25, 2024
Automation, Oil, Inverell, Growth, BMO, COVID-19, Data, Travel, Imperial, Depreciation, Insurance, Health Canada, Cannabis, Gross margin, SKU, Love, Human back, Fire, Cadastre, Marketing, RSU, Drug

The impairments recognized in 2022 include impairments related to the closure of the Auxly Annapolis facilities.

Key Points: 
  • The impairments recognized in 2022 include impairments related to the closure of the Auxly Annapolis facilities.
  • Wages and benefits were $16.3 million for the year, as compared to $18.7 million for the same period of 2022.
  • Office and administrative expenses were $10.4 million for the year, $1.2 million lower than the same period in 2022.
  • Please see the Company's MD&A dated March 24, 2024, under "Non-GAAP Measures" for a further description of the following financial and supplementary financial measures.

Travelling for Easter? The Canada Border Services Agency gives tips for a smooth trip

Retrieved on: 
Friday, March 22, 2024
Firearm, Narcotic, Friends, Canadian Food Inspection Agency, Letter, Oil, Poultry, Travel, BIS, CBSA, Child, Bird, Tobacco, Food, Health Canada, Cannabis, Holiday, Atmosphere, Water, Arrest, Safety, THC, Family, AIRS, Movement, Canada Border Services Agency, Cannabidiol, Drug

OTTAWA, ON, March 22, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border over the Easter long weekend.

Key Points: 
  • OTTAWA, ON, March 22, 2024 /CNW/ - The Canada Border Services Agency (CBSA) reminds travellers of what to expect when crossing the border over the Easter long weekend.
  • Here are some tips to help you plan for your trip:
    Plan ahead, expect delays and check border wait times .
  • Border services officers are always watching for missing children , and in the absence of the letter, officers may ask additional questions.
  • You may also contact Border Information Service (BIS) line toll-free within Canada at 1-800-461-9999 for more information

Cannabis Act legislative review Expert Panel welcomes the tabling of its final report

Retrieved on: 
Thursday, March 21, 2024
Psychosis, Health, Department of Finance Canada, First Nations, Organization, Schizophrenia, Cannabis Act, Act, Pharmacy, Public, Research, Health Canada, Parliament, Cannabis, Government, Drug

OTTAWA, ON, March 21, 2024 /CNW/ - Today, the independent Expert Panel conducting the review of the Cannabis Act welcomed the tabling of its final report in both houses of Parliament.

Key Points: 
  • OTTAWA, ON, March 21, 2024 /CNW/ - Today, the independent Expert Panel conducting the review of the Cannabis Act welcomed the tabling of its final report in both houses of Parliament.
  • The report, a legislative requirement under the Act, reviews progress toward meeting the Act's objectives and recommends changes to the Act and its supporting regulations and policies.
  • "The Cannabis Act is a dramatic departure from prohibition, which had been the approach to controlling cannabis for the past century.
  • The Expert Panel appreciates the opportunity to have undertaken this critical review of the cannabis framework in Canada.

Government of Canada Tables Final Report of the Legislative Review of the Cannabis Act

Retrieved on: 
Thursday, March 21, 2024
Addiction, First Nations, Mental health, Government, Crime, Face, Panel, Risk, Cannabis Act, Public, Law enforcement, The Honourable, Sale, Policy, Health Canada, Cannabis, Woman, Progress, Indigenous peoples, Safety, Legislation, Person, Drug

OTTAWA, ON, March 21, 2024 /CNW/ - In 2018, the Government of Canada introduced the Cannabis Act , which put into place a legal framework that takes a comprehensive public health approach to cannabis.

Key Points: 
  • OTTAWA, ON, March 21, 2024 /CNW/ - In 2018, the Government of Canada introduced the Cannabis Act , which put into place a legal framework that takes a comprehensive public health approach to cannabis.
  • In accordance with the Act, the Honourable Mark Holland, Minister of Health and the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health released the final report of the Legislative Review of the Cannabis Act.
  • This final report is the result of the extensive work conducted by the independent Expert Panel, chaired by Morris Rosenberg, that led the review over the last 18 months.
  • "I would like to thank Chair Rosenberg and the members of the Expert Panel for their enormous effort and dedication in leading the first-ever Legislative Review of the Cannabis Act.

Government of Canada Announces Reimbursements and Deductions under the Canada Health Act

Retrieved on: 
Thursday, March 21, 2024
Transfer, Federation, Patient, CHT, Health Canada, Outline, Annual report, Canada Health Act, CHA, PTS, Government, Policy, Health insurance

The goal of the Canada Health Act and mandatory Canada Health Transfer (CHT) deductions has always been to ensure patients do not pay out of pocket for medically necessary services.

Key Points: 
  • The goal of the Canada Health Act and mandatory Canada Health Transfer (CHT) deductions has always been to ensure patients do not pay out of pocket for medically necessary services.
  • The reimbursements recognize the work being done to protect patients from inappropriate charges and improve universal access to health care services.
  • No Canadian should ever pay out of pocket for medically necessary services covered under the Canada Health Act.
  • The Canada Health Act Annual Reports include Reimbursement Action Plans that outline what PTs have done to eliminate patient charges.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Groupe Marcelle inc. was fined $500,000 for violating the Canadian Environmental Protection Act, 1999

Retrieved on: 
Tuesday, March 19, 2024
Registry, Health, Government, Environment, PFAS, Marcelle, Biophysical environment, Per- and polyfluoroalkyl substances, Risk, Act, Knowledge, Government of Canada, Land degradation, Health Canada, Climate change, Skin, Water, Safety, Lise Watier, Cosmetics, Fund, Marketing, Lip, Court, PFA, Annabel, Food

On March 19, 2024, Groupe Marcelle inc. was ordered by the Court of Québec, at the Montréal Courthouse, to pay a fine of $500,000.

Key Points: 
  • On March 19, 2024, Groupe Marcelle inc. was ordered by the Court of Québec, at the Montréal Courthouse, to pay a fine of $500,000.
  • The company pleaded guilty to one count of violating the Canadian Environmental Protection Act, 1999.
  • In this case, the marketing of cosmetic products containing Perfluorononyl Dimethicone is considered a new activity under the Canadian Environmental Protection Act, 1999.
  • By using Perfluorononyl Dimethicone in cosmetic products, without having previously provided the government with the required regulatory information, Groupe Marcelle inc. has committed an offence under subsection 81(4) of the Canadian Environmental Protection Act, 1999.